Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia

Leukemia

Volumn 26, Issue 4, 2012, Pages 682-692

  Stumpel, D J P M ^a   Schneider, P ^a   Seslija, L ^a   Osaki, H ^b   Williams, O ^b   Pieters, R ^a   Stam, R W ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

connectivity map; HDAC inhibitors; infant ALL; MLL

Indexed keywords

ENTINOSTAT; PANOBINOSTAT; ROMIDEPSIN; TRICHOSTATIN A; TSA; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; VPA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; GENE EXPRESSION; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LEUKEMIA CELL; PRIORITY JOURNAL;

EID: 84859633464     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.278     Document Type: Article

References (49)

1. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250. (Pubitemid 47082422)
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043. (Pubitemid 351389536)
3. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009; 23: 1490-1499.
4. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997; 94: 13950-13954. (Pubitemid 28009690)
5. Jansen MW, Corral L, van der Velden VH, Panzer-Grumayer R, Schrappe M, Schrauder A et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007; 21: 633-641. (Pubitemid 46444545)
6. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 2010; 115: 3570-3579.
7. Ernst P, Fisher JK, Avery W, Wade S, Foy D, Korsmeyer SJ. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell 2004; 6: 437-443. (Pubitemid 38364574)
8. Gan T, Jude CD, Zaffuto K, Ernst P. Developmentally induced Mll1 loss reveals defects in postnatal haematopoiesis. Leukemia 2010; 24: 1732-1741.
9. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
10. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115: 2835-2844.
11. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007; 16: 92-106. (Pubitemid 46152547)
12. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009; 114: 5490-5498.
13. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008; 22: 3403-3408.
14. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14: 355-368.
15. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935. (Pubitemid 44497995)
16. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106: 2484-2490. (Pubitemid 41510823)
17. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, HeyenbrokMW et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-2336.
18. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-210. (Pubitemid 34679544)
19. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7: 54-60. (Pubitemid 46020847)
20. Stam RW, den Boer ML, Schneider P, Meier M, Beverloo HB, Pieters R. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007; 92: 1565-1568. (Pubitemid 350144134)
21. Smyth GK. Limma: linear models for microarray data. In: Gentleman VC SD R, Irizarry R, Huber W (eds). Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer: New York, 2005, pp 397-420.
22. Benjamini Y HY. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995; 57: 289-300.
23. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet 2006; 38: 500-501.
24. Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 2010; 115: 4798-4809.
25. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
26. Pieters R. Infant acute lymphoblastic leukemia: lessons learned and future directions. Curr Hematol Malig Rep 2009; 4: 167-174.
27. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10: 321-330. (Pubitemid 44512193)
28. Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 2004; 89: 419-426. (Pubitemid 38798546)
29. Stams WA, den Boer ML, Beverloo HB, Kazemier KM, van Wering ER, Janka-Schaub GE et al. Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia. Haematologica 2005; 90: 1697-1699. (Pubitemid 41814997)
30. Kramer OH, Muller S, Buchwald M, Reichardt S, Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J 2008; 22: 1369-1379. (Pubitemid 351656778)
31. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia 1996; 10: 372-377. (Pubitemid 26102900)
32. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10: 1107-1117. (Pubitemid 35453828)
33. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-990.
34. Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. Leukemogenic transformation by HOXA cluster genes. Blood 2010; 115: 2910-2918.
35. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem 2002; 277: 25026-25031. (Pubitemid 34951806)
36. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 376-387. (Pubitemid 40637829)
37. Rensen WM, Mangiacasale R, Ciciarello M, Lavia P. The GTPase Ran: regulation of cell life and potential roles in cell transformation. Front Biosci 2008; 13: 4097-4121. (Pubitemid 351611596)
38. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997; 231: 509-513. (Pubitemid 27214343)
39. Liu H, Wang M, Li M, Wang D, Rao Q, Wang Y et al. Expression and role of DJ-1 in leukemia. Biochem Biophys Res Commun 2008; 375: 477-483.
40. Kitzing TM, Sahadevan AS, Brandt DT, Knieling H, Hannemann S, Fackler OT et al. Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. Genes Dev 2007; 21: 1478-1483. (Pubitemid 46955720)
41. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA 2003; 100: 8342-8347. (Pubitemid 36842547)
42. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 2009; 457: 887-891.
43. Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 2003; 17: 2249-2250. (Pubitemid 37428400)
44. Popov N, Schulein C, Jaenicke LA, Eilers M. Ubiquitylation of the amino terminus of Myc by SCF(beta-TrCP) antagonizes SCF(Fbw7)-mediated turnover. Nat Cell Biol 2010; 12: 973-981.
45. Parada LF, Land H, Chen A, Morganstern J, Weinberg RA. Cooperation between cellular oncogenes in the transformation of primary rat embryo fibroblasts. Prog Med Virol 1985; 32: 115-128.
46. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24: 166-173. (Pubitemid 46630509)
47. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-5417.
48. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12: 4628-4635. (Pubitemid 44297814)
49. Burbury KL, Bishton MJ, Johnstone RW, Dickinson MJ, Szer J, Prince HM. MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). Ann Hematol 2010; 90: 847-849.